SAV1 and cancer: In the majority of cancers, the overall genetic mutation rate of Hippo pathway components is relatively low, and high YAP/TAZ activity is not correlated with genetic mutations of the Hippo pathway.39 Our work first demonstrated that, in MM, the abnormality of the HIPPO pathway-initiating protein SAV1 is not attributed to genetic mutations but to RNA methylation modification.